THRX实时信号 | 通过Getagraph.com最大化利润

购买 110336 min ago

@ $4.06

发出时间: 13 Feb 2024 @ 05:00

回报率: 0.12%

Live Chart Being Loaded With Signals

Commentary (14 Feb 2024 @ 04:59):

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients...

Stats
今日成交量	677 694
平均成交量	849 600
市值	181.50M
EPS	$0 ( 2024-03-14 )
下一个收益日期	( $0 ) 2024-05-11
Last Dividend	$0.250 ( 2015-09-08 )
Next Dividend	$0 ( N/A )
P/E	-3.03
ATR14	$0.0670 (1.65%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-14	Yi Kathy	Sell	3 250	Restricted Stock Units
2024-02-14	Yi Kathy	Sell	99 634	Stock Option (Right to Buy)
2024-02-14	Stein Steven H	Sell	3 250	Restricted Stock Units
2024-02-14	Orbimed Advisors Llc	Sell	650 600	Common Stock
2024-02-14	Hayden Donald J Jr	Sell	10 000	Common Stock

INSIDER POWER
-12.61
Last 94 transactions
Buy: 24 821 782 \| Sell: 19 785 944

音量相关性

長: 0.04 (neutral)

短: 0.00 (neutral)

Signal:(59.853) Neutral

Theseus Pharmaceuticals, 相关性

10 最正相关
PXLW	0.931
ADXN	0.921
LIAN	0.92
TNXP	0.917
JFIN	0.914
DSKE	0.906
SPRB	0.904
SRRK	0.902
MEUSW	0.897
LX	0.895

10 最负相关
GRPH	-0.881
AHPI	-0.842
EA	-0.834
TUEM	-0.826
VERA	-0.818
MTEX	-0.814
LCAP	-0.812

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Theseus Pharmaceuticals, 相关性 - 货币/商品

-0.52
( weak negative )

0.34
( neutral )

0.00
( neutral )

-0.15
( neutral )

0.66
( moderate )

0.48
( neutral )

Theseus Pharmaceuticals, 财务报表

Annual	2022
营收:	$0
毛利润:	$-438 000 (0.00 %)
EPS:	$-1.220

FY	2022
营收:	$0
毛利润:	$-438 000 (0.00 %)
EPS:	$-1.220

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-2.84

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.010

Financial Reports:

No articles found.

Theseus Pharmaceuticals, Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Theseus Pharmaceuticals, Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Information

First Dividend	$0.250	2014-08-26
Last Dividend	$0.250	2015-09-08
Next Dividend	$0	N/A
Payout Date	2015-09-30
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	$1.250	--
Avg. Dividend % Per Year	0.00%	--
Score	1.55	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-06-19)

$0 Estimate 0.00 %

Dividend Stability

0.03 Very Bad

Dividend Score

1.55

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	-0.238	1.200	-7.94	-9.52	[0 - 0.3]
returnOnEquityTTM	-0.245	1.500	-3.83	-5.75	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	29.93	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	29.29	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	6.70	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0156	-1.500	9.74	-10.00	[0 - 0.6]
interestCoverageTTM	88.35	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	-1.133	2.00	-0.378	-0.755	[0 - 30]
freeCashFlowPerShareTTM	-1.134	2.00	-0.567	-1.134	[0 - 20]
debtEquityRatioTTM	0.0163	-1.500	9.93	-10.00	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-13.58	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				1.984

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-3.19	1.000	-0.423	0	[1 - 100]
returnOnEquityTTM	-0.245	2.50	-2.46	-5.75	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.134	2.00	-0.378	-1.134	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-1.133	2.00	-0.378	-0.755	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.00632	1.500	-3.29	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				-1.553

Theseus Pharmaceuticals,

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.